{
    "patient": {
        "Name": "Brandi Thomas",
        "DateOfBirth": "1976-07-21",
        "Sex": "Female",
        "Diagnosis": "Triple-negative breast cancer",
        "BodyPart": "Breast",
        "Physician": "Dr. Timothy Johnson",
        "TreatingInstitution": "Yates, Farley and Roberts"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Breast",
            "CollectedDate": "2023-04-30",
            "ReceivedDate": "2023-05-04",
            "TumorPercentage": "52%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2023-05-05",
            "ReceivedDate": "2023-05-05"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "CCND3",
                "DNA Alteration": "c.766_776del11",
                "GeneMutation": "p.R256fs*64 Frameshift-GOF",
                "VariantAlleleFraction": "30.18%"
            },
            {
                "Gene": "ZEB2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.H1038R Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "31.52%"
            },
            {
                "Gene": "GNAS",
                "DNA Alteration": "c.601C>T",
                "GeneMutation": "p.Q125R Nonsense-GOF",
                "VariantAlleleFraction": "2.26%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "DICER1",
                "DNA Alteration": "c.5428G>C",
                "GeneMutation": "p.W1831* Spliceregionvariant-GOF",
                "VariantAlleleFraction": "16.85%"
            },
            {
                "Gene": "CDC73",
                "DNA Alteration": "c.1A>G",
                "GeneMutation": "p.E1813G Stopgain-LOF",
                "VariantAlleleFraction": "10.25%"
            },
            {
                "Gene": "EGFR",
                "DNA Alteration": "c.1474A>C",
                "GeneMutation": "p.P772_H773insNPH Stopgain-LOF",
                "VariantAlleleFraction": "8.07%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "KLF4",
            "MAPK1",
            "FGFR1"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "46 m/Mb",
            "Tmbpercentile": "95%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Stable"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "SMO",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A374E Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "9.67%"
            },
            {
                "Gene": "RB1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.F650S Spliceregionvariant-LOF",
                "VariantAlleleFraction": "9.37%"
            },
            {
                "Gene": "IDH1",
                "DNA Alteration": "c.394C>G",
                "GeneMutation": "p.R132X Stopgain-LOF",
                "VariantAlleleFraction": "8.63%"
            },
            {
                "Gene": "DICER1",
                "DNA Alteration": "c.5439G>T",
                "GeneMutation": "p.E1813K Spliceregionvariant-LOF",
                "VariantAlleleFraction": "7.0%"
            },
            {
                "Gene": "SF3B1",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.K741X Nonsense-GOF",
                "VariantAlleleFraction": "5.19%"
            },
            {
                "Gene": "SMO",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.A374E Nonsense-LOF",
                "VariantAlleleFraction": "9.61%"
            }
        ],
        "Germline": [
            {
                "Gene": "CDC73",
                "DNA Alteration": "c.1A>G",
                "GeneMutation": "p.M1V Spliceregionvariant-LOF",
                "Condition": "her"
            },
            {
                "Gene": "PHF6",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R225X Nonsense-LOF",
                "Condition": "trial"
            }
        ]
    },
    "low coverage regions": [
        "FLT3",
        "MTOR",
        "HDAC2"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "CCND3",
                "DNA Alteration": "c.766_776del11",
                "GeneMutation": "p.R256fs*64 Frameshift-GOF",
                "description": "RBM10 encodes a protein that contains a RNA-binding motif and interacts with RNA homopolymers, and is thought to function in regulating alternative splicing. Loss of function mutations and copy number loss of RBM10 are associated with cancer progression.",
                "VariantAlleleFraction": "30.18%"
            },
            {
                "Gene": "ZEB2",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.H1038R Missensevariant(exon2)-GOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "31.52%"
            },
            {
                "Gene": "GNAS",
                "DNA Alteration": "c.601C>T",
                "GeneMutation": "p.Q125R Nonsense-GOF",
                "description": "STK11 (LKB1) encodes an enzyme in the serine/threonine kinase family that is responsible for maintaining energy metabolism and cellular polarization through the activation of AMP-activated protein kinase and other members of the AMPK family. The enzyme also acts as a tumor suppressor by regulating cell growth. Loss of function mutations, copy number loss, epigenetic variation, and underexpression of STK11 are associated with cancer progression.",
                "VariantAlleleFraction": "2.26%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "DICER1",
                "DNA Alteration": "c.5428G>C",
                "GeneMutation": "p.W1831* Spliceregionvariant-GOF",
                "description": "KRAS is a GDP/GTP binding protein that acts as an intracellular signal transducer. KRAS is involved in several pathways involved in cellular proliferation and survival, including the PI3K-AKT-mTOR pathway and the Ras-Raf-MEK-ERK pathway. Activating mutations, copy number gains, and overexpression of KRAS are associated with cancer progression.",
                "VariantAlleleFraction": "16.85%"
            },
            {
                "Gene": "CDC73",
                "DNA Alteration": "c.1A>G",
                "GeneMutation": "p.E1813G Stopgain-LOF",
                "description": "RBM10 encodes a protein that contains a RNA-binding motif and interacts with RNA homopolymers, and is thought to function in regulating alternative splicing. Loss of function mutations and copy number loss of RBM10 are associated with cancer progression.",
                "VariantAlleleFraction": "10.25%"
            },
            {
                "Gene": "EGFR",
                "DNA Alteration": "c.1474A>C",
                "GeneMutation": "p.P772_H773insNPH Stopgain-LOF",
                "description": "RBM10 encodes a protein that contains a RNA-binding motif and interacts with RNA homopolymers, and is thought to function in regulating alternative splicing. Loss of function mutations and copy number loss of RBM10 are associated with cancer progression.",
                "VariantAlleleFraction": "8.07%"
            }
        ]
    },
    "clinical history": {
        "Date": "2023-04-28"
    },
    "other": {
        "ReportId": "8347",
        "ReportDate": "2023-04-30",
        "SignedBy": "Timothy Johnson",
        "Supervisor": "Dr. Deborah Williams"
    }
}